Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Ando, K.; Akimoto, K.; Sato, H.; Manabe, R.; Kishino, Y.; Homma, T.; Kusumoto, S.; Yamaoka, T.; Tanaka, A.; Ohmori, T.; Sagara, H. Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. Cancers 2020, 12, 942. https://doi.org/10.3390/cancers12040942
Ando K, Akimoto K, Sato H, Manabe R, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Sagara H. Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. Cancers. 2020; 12(4):942. https://doi.org/10.3390/cancers12040942
Chicago/Turabian StyleAndo, Koichi; Akimoto, Kaho; Sato, Hiroki; Manabe, Ryo; Kishino, Yasunari; Homma, Tetsuya; Kusumoto, Sojiro; Yamaoka, Toshimitsu; Tanaka, Akihiko; Ohmori, Tohru; Sagara, Hironori. 2020. "Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis" Cancers 12, no. 4: 942. https://doi.org/10.3390/cancers12040942